Beneficial effects of metformin on haemostasis and vascular function in man
Tóm tắt
Từ khóa
Tài liệu tham khảo
Davie, 1964, Waterfall sequence for intrinsic blood clotting, Science, 145, 1310, 10.1126/science.145.3638.1310
Macfarlane, 1964, An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier, Nature, 202, 498, 10.1038/202498a0
Nemerson, 1966, The reaction between bovine brain tissue factor and factors VII and X, Biochemistry, 5, 601, 10.1021/bi00866a029
Broze, 1995, Tissue factor pathway inhibitor and the revised theory of coagulation, Ann Rev Med, 46, 103, 10.1146/annurev.med.46.1.103
Frank, 2001, Role of contact system activation in hemodialyzer-induced thrombogenicity, Kidney Int, 60, 1972, 10.1046/j.1523-1755.2001.00009.x
Mackman, 1997, Regulation of the tissue factor gene, Thromb Haemost, 78, 747, 10.1055/s-0038-1657623
Marmur, 1996, Identification of active tissue factor in human coronary atheroma, Circulation, 94, 1226, 10.1161/01.CIR.94.6.1226
Balasubramanian, 2002, Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: realtime fluorescence images of thrombus formation and propagation under defined flow conditions, Blood, 100, 2787, 10.1182/blood-2002-03-0902
Mullin, 2000, Decreased lateral aggregation of a variant recombinant fibrinogen provides insight into the polymerisation mechanism, Biochemistry, 39, 9843, 10.1021/bi000045c
Weisel, 1993, The sequence of cleavage of fibrinopeptides from fibrinogen is important for protofibril formation and enhancement of lateral aggregation in fibrin clots, J Mol Biol, 232, 285, 10.1006/jmbi.1993.1382
Lorand, 2000, Sol Sherry Lecture in Thrombosis: Research on clot stabilization provides clues for improving thrombolytic therapies, Arterioscler Thromb Vasc Biol, 20, 2, 10.1161/01.ATV.20.1.2
Sakata, 1980, Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin- stabilizing factor, J Clin Invest, 65, 290, 10.1172/JCI109671
Gaffney, 2001, Fibrin degradation products. A review of structures found in vitro and in vivo, Ann NY Acad Sci, 936, 594, 10.1111/j.1749-6632.2001.tb03547.x
Wiman, 1979, On the mechanism of the reaction between human alpha 2-antiplasmin and plasmin, J Biol Chem, 254, 9291, 10.1016/S0021-9258(19)86843-6
Kruithof, 1984, Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma, Blood, 64, 907, 10.1182/blood.V64.4.907.907
Macfarlane, 2001, Proteinase-activated receptors, Pharmacol Rev, 53, 245
Esmon, 1981, Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C, Proc Natl Acad Sci USA, 78, 2249, 10.1073/pnas.78.4.2249
Petersen S, Rayner M, Press V. Coronary Heart Disease Statistics, In, British Heart Foundation Statistics Database 2000. British Heart Foundation, 2000.
Rayner M, Petersen S. European Cardiovascular Disease Statistics. 2000.
Reaven, 1988, Role of insulin resistance in human disease, Diabetes, 37, 1595, 10.2337/diabetes.37.12.1595
Hollenbeck, 1987, Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance, J Clin Endocrinol Metab, 64, 1169, 10.1210/jcem-64-6-1169
Zavaroni, 1989, Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance, N Engl J Med, 320, 702, 10.1056/NEJM198903163201105
Vague, 1986, Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects, Metabolism, 35, 250, 10.1016/0026-0495(86)90209-X
Juhan-Vague, 1987, Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1, Diabete Metab, 13, 331
Potter van Loon, 1993, The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance, Metabolism, 42, 945, 10.1016/0026-0495(93)90005-9
Nilsson, 1994, von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome, J Int Med, 235, 419, 10.1111/j.1365-2796.1994.tb01097.x
Carter, 1998, Determinants of tPA antigen and associations with coronary artery disease and acute cerebrovascular disease, Thromb Haemost, 80, 632
Meigs, 2000, Hyperinsulinemia, hyperglycaemia, and impaired hemostasis, the Framingham Offspring Study, JAMA, 283, 221, 10.1001/jama.283.2.221
Mansfield, 1997, PAI-1 concentrations in first-degree relatives of patients with non- insulin-dependent diabetes, metabolic and genetic associations, Thromb Haemost, 77, 357, 10.1055/s-0038-1655968
Juhan-Vague, 1996, Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris, Circulation, 94, 2057, 10.1161/01.CIR.94.9.2057
Juhan-Vague, 1993, Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1,500 patients with angina pectoris. The ECAT Angina Pectoris Study Group, Arterioscler Thromb, 13, 1865, 10.1161/01.ATV.13.12.1865
Sironi, 1996, Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL, Arterioscler Thromb Vasc Biol, 16, 89, 10.1161/01.ATV.16.1.89
Alessi, 1997, Production of plasminogen activator inhibitor 1 by human adipose tissue, possible link between visceral fat accumulation and vascular disease, Diabetes, 46, 860, 10.2337/diabetes.46.5.860
Hotamisligil, 1996, IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α, Science, 271, 665, 10.1126/science.271.5249.665
Samad, 1996, Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide, J Clin Invest, 97, 37, 10.1172/JCI118404
Mansfield, 1995, Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus, Thromb Haemost, 74, 842, 10.1055/s-0038-1649834
Eriksson, 1995, Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction, Proc Natl Acad Sci USA, 92, 1851, 10.1073/pnas.92.6.1851
Eriksson, 1998, Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia, Arterioscler Thromb Vasc Biol, 18, 20, 10.1161/01.ATV.18.1.20
Meade, 1986, Haemostatic function and ischaemic heart disease, principal results of the Northwick Park Heart Study, Lancet, 2, 533, 10.1016/S0140-6736(86)90111-X
Heinrich, 1994, Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM Study in healthy men, Arterioscler Thromb Vasc Biol, 14, 54, 10.1161/01.ATV.14.1.54
Smith, 1997, Haemostatic factors as predictors of ischaemic heart disease and stroke in the Edinburgh Artery Study, Arterioscler Thromb, 17, 3321, 10.1161/01.ATV.17.11.3321
Lane, 1996, Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and France but is not a strong indicator of MI risk in the ECTIM study, Atherosclerosis, 119, 119, 10.1016/0021-9150(95)05638-6
Folsom, 1997, Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study, Circulation, 96, 1102, 10.1161/01.CIR.96.4.1102
Scarabin, 1998, Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction. The Prime Study, Thromb Haemost, 80, 749, 10.1055/s-0037-1615353
Meade, 1993, Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study, Lancet, 342, 1076, 10.1016/0140-6736(93)92062-X
Heywood, 1996, Factor VII gene polymorphisms, factor VII, C levels and features of insulin resistance in noninsulin dependent diabetes mellitus, Thromb Haemost, 75, 401, 10.1055/s-0038-1650286
Haffner, 1988, Increased insulin concentrations in nondiabetic offspring of diabetic parents, N Engl J Med, 319, 1297, 10.1056/NEJM198811173192001
Mansfield, 1996, Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM, Circulation, 94, 2171, 10.1161/01.CIR.94.9.2171
Zitoun, 1996, Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidaemias, Arterioscler Thromb Vasc Biol, 16, 77, 10.1161/01.ATV.16.1.77
Ganda, 1992, Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes, Diabetes Care, 15, 1245, 10.2337/diacare.15.10.1245
Landin, 1990, Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1, Metabolism, 39, 1044, 10.1016/0026-0495(90)90164-8
Yudkin, 1988, Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey, Lancet, 2, 530, 10.1016/S0140-6736(88)92657-8
Mykkanen, 1998, Microalbuminuria is associated with insulin resistance in nondiabetic subjects, the insulin resistance atherosclerosis study, Diabetes, 47, 793, 10.2337/diabetes.47.5.793
Greaves, 1997, Fibrinogen and von Willebrand factor in IDDM, relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate, the EURODIAB IDDM Complications Study, Diabetologia, 40, 698, 10.1007/s001250050736
Bruno, 1996, Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus, Ann Int Med, 125, 653, 10.7326/0003-4819-125-8-199610150-00005
Festa, 2000, Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects, The Insulin Resistance Atherosclerosis Study, Kidney Int, 58, 1703, 10.1046/j.1523-1755.2000.00331.x
Mennen, 2001, Microalbuminuria and markers of the atherosclerotic process, the D.E. S.I.R. study, Atherosclerosis, 154, 163, 10.1016/S0021-9150(00)00451-2
Bailey, 1988, Metformin revisited. Its actions and indications for use, Diab Med, 5, 315, 10.1111/j.1464-5491.1988.tb00996.x
Chakrabarti, 1965, Fibrinolytic effect of metformin in coronary artery disease, Lancet, II, 256, 10.1016/S0140-6736(65)92383-4
Hocking, 1967, Effects of Biguanides and atromid on fibrinolysis, J Atheroscl Res, 7, 121, 10.1016/S0368-1319(67)80074-7
Heikinheimo, 1969, Metformin and fibrinolysis, Scand J Haematol, 6, 256, 10.1111/j.1600-0609.1969.tb02410.x
Vague, 1987, Metformin decreases the high plasminogen activator inhibition activity, plasma insulin and triglyceride levels in non-diabetic obese subjects, Thromb Haemostas, 57, 326, 10.1055/s-0038-1651126
Anfosso, 1993, Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2, Metformin inhibits the stimulating effect of insulin, J Clin Invest, 91, 2185, 10.1172/JCI116445
Sadananda, 1974, Effect of metformin on fibrinolytic activity in diabetes mellitus, J Diabet Assoc India, 14, 33
Cho, 1992, Plasma tPA and PAI-1 antigen concentrations in non-insulin dependent diabetic patients, effects of treatment modality on fibrinolysis, Korean Journal of Internal Medicine, 7, 81, 10.3904/kjim.1992.7.2.81
Grant, 1991, Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients, Diabetic Medicine, 8, 361, 10.1111/j.1464-5491.1991.tb01610.x
Nagi, 1993, Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects, Diabetes Care, 16, 621, 10.2337/diacare.16.4.621
Grant, 1996, The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes, Diabetes Care, 19, 64, 10.2337/diacare.19.1.64
Grant, 1998, Metformin reduces circulating factor VII concentrations in patients with type 2 diabetes mellitus, Thrombosis and Haemostasis, 80, 209, 10.1055/s-0037-1615172
Standeven, 2002, The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerisation and fibrin clot formation, Diabetes, 51, 189, 10.2337/diabetes.51.1.189
Tanaka, 1997, Inhibitory effect of metformin on formation of advanced glycation end products, Current Therapeutic Research, 56, 693, 10.1016/S0011-393X(97)80103-8
Gregorio, 1999, Poorly controlled elderly type 2 diabetic patients, the effects of increasing sulphonylurea dosages or adding metformin, Diabetic Medicine, 16, 1016, 10.1046/j.1464-5491.1999.00201.x
Gargiulo, 2002, Metformin decreases platelet superoxide anion production in diabetic patients, Diabetes/Metabolism Research Reviews, 18, 156, 10.1002/dmrr.282
Vinik, 2001, Platelet dysfunction in type 2 diabetes, Diabetes Care, 24, 1476, 10.2337/diacare.24.8.1476
Sirtori, 1984, Metformin improves peripheral vascular flow in nonhyperlipidemic patients with arterial disease, J Cardiovascular Pharmacology, 6, 914, 10.1097/00005344-198409000-00027
Marfella, 1996, Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients, Diabetes Care, 19, 934, 10.2337/diacare.19.9.934
Asagami, 2002, Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes, Metabolism, 51, 843, 10.1053/meta.2002.33349
Jansson, 1996, The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM, Diabetes Care, 19, 160, 10.2337/diacare.19.2.160
Grant, 1995, The effects of metformin on cardiovascular risk factors, Diabetes/Metabolism Reviews, 11, S43, 10.1002/dmr.5610110507
1998, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group, Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8
Knowler, 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, New England Journal of Medicine, 346, 393, 10.1056/NEJMoa012512